AzTrials
AzTrials

Angioembolization in Knee OsteoarthritisNCT07736248

Embolization of Genicular Arteries for Treatment of Symptomatic Knee Osteoarthritis

A study testing genicular artery embolization, Calibrated microspheres (100-300 µm) and Microcatheter in people with Angioembolization in Knee Osteoarthritis, run by Assiut University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

To evaluate the efficacy and safety of genicular artery embolization in patients with symptomatic knee osteoarthritis refractory to conservative treatment. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Angioembolization in Knee Osteoarthritis
What is being tested?
genicular artery embolization, Calibrated microspheres (100-300 µm) and Microcatheter
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
No sites listed yet
Study dates
Aug 2026to Sep 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of knee osteoarthritis according to the criteria of the American College of Rheumatology.
  • Radiographic evidence of osteoarthritis corresponding to Kellgren-Lawrence grades I-III.
  • Moderate to severe knee pain for at least 6 months. Visual Analog Scale (VAS) score ≥5.
  • Failure of conservative treatment for at least 3 months including analgesics, non-steroidal anti-inflammatory drugs, physiotherapy, lifestyle modification, or intra-articular injections.

Who cannot join

  • Kellgren-Lawrence grade IV osteoarthritis.
  • Previous knee arthroplasty.
  • Inflammatory arthropathies such as rheumatoid arthritis, psoriatic arthritis, or gout.
  • Active local or systemic infection.
  • Severe peripheral arterial disease.
  • Coagulation disorders.
Show all 10Show fewer
  • Renal insufficiency (raised renal chemistry).
  • Pregnancy.
  • Known allergy to iodinated contrast media.
  • Refuse to provide written informed consent

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Rehab Awad Mohamed contact

2+01011511722

RehabAwad@aun.edu.eg

About this study

Official title: Super Selective Angiographic Catheterization and Embolization of Genicular Arteries for Treatment of Symptomatic Knee Osteoarthritis

To evaluate the efficacy and safety of genicular artery embolization in patients with symptomatic knee osteoarthritis refractory to conservative treatment.

Being tested
genicular artery embolization, Calibrated microspheres (100-300 µm), Microcatheter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • genicular artery embolizationProcedure or surgery

    Super-selective embolization of abnormal genicular arteries supplying the painful synovium in patients with symptomatic knee osteoarthritis.

  • Calibrated microspheres (100-300 µm)Device

    Embolic microspheres used for occlusion of the targeted genicular arteries during embolization.

  • MicrocatheterDevice

    A 2.0-2.4 Fr microcatheter used for super-selective catheterization of the genicular arteries.

Study groups in NCT07736248
Study groupRoleWhat they receive
genicular artery embolizationExperimentalParticipants with symptomatic knee osteoarthritis will undergo super-selective genicular artery embolization using calibrated microspheres. Clinical outcomes will be assessed using pain and functional scores during follow-up.
Receives: Procedure: genicular artery embolization; Device: Calibrated microspheres (100-300 µm); Device: Microcatheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change from baseline in visual analog scale (VAS) pain score

    pain intensity measured using the 10-cm visual analog scale (VAS). scores range from 0 to 10, with higher scores indicating greater pain. The change from baseline to 6 months after genicular artery embolization will be assessed.

    Measured: Baseline and 6 months after the Procedure

Secondary outcomes (3)

  1. Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score

    Knee pain, stiffness, and physical function will be assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The total WOMAC score ranges from 0 to 96, where 0 indicates no symptoms and 96 indicates the most severe symptoms. Higher scores indicate worse pain, stiffness, and functional limitation.

    Measured: Baseline, 3 months, and 6 months after the procedure

  2. Change from Baseline in Health-Related Quality of Life Score (EQ-5D-5L)

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The EQ-5D-5L descriptive system consists of five dimensions, each with five levels, and responses are converted into a utility index score ranging from values below 0 (health states worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life. Assessments will be performed at baseline, 3 months, and 6 months after the procedure.

    Measured: Baseline and 6 months after the procedure

  3. Technical Success Rate of Genicular Artery Embolization

    Technical success is defined as successful selective catheterization and embolization of all target genicular arteries with completion of the planned procedure.

    Measured: During the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2026
  2. Study startAug 2026 (estimated)
  3. Primary completionAug 2028 (estimated)
  4. Study completionSep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07736248
Sponsor's protocol ID
angioembolization in knee OA
Status last verified
Jul 2026
First submitted
21 Jul 2026
Last updated
4 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Crawford DC, Miller LE, Block JE. Conservative management of symptomatic knee osteoarthritis: a flawed strategy? Orthop Rev (Pavia). 2013 Feb 22;5(1):e2. doi: 10.4081/or.2013.e2. Print 2013 Feb 22.

    PubMed 23705060

  • Lyu SR, Chiang JK, Tseng CE. Medial plica in patients with knee osteoarthritis: a histomorphological study. Knee Surg Sports Traumatol Arthrosc. 2010 Jun;18(6):769-76. doi: 10.1007/s00167-009-0946-2. Epub 2009 Oct 14.

    PubMed 19826785

  • Bohnsack M, Meier F, Walter GF, Hurschler C, Schmolke S, Wirth CJ, Ruhmann O. Distribution of substance-P nerves inside the infrapatellar fat pad and the adjacent synovial tissue: a neurohistological approach to anterior knee pain syndrome. Arch Orthop Trauma Surg. 2005 Nov;125(9):592-7. doi: 10.1007/s00402-005-0796-4.

    PubMed 15891922

  • Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, McWilliams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage. 2007 Jul;15(7):743-51. doi: 10.1016/j.joca.2007.01.020. Epub 2007 Mar 21.

    PubMed 17376709

  • Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol. 2012 May 29;8(7):390-8. doi: 10.1038/nrrheum.2012.80.

    PubMed 22641138

  • Kurien T, Kerslake RW, Graven-Nielsen T, Arendt-Nielsen L, Auer DP, Edwards K, Scammell BE, Petersen KK. Chronic postoperative pain after total knee arthroplasty: The potential contributions of synovitis, pain sensitization and pain catastrophizing-An explorative study. Eur J Pain. 2022 Oct;26(9):1979-1989. doi: 10.1002/ejp.2018. Epub 2022 Aug 19.

    PubMed 35959735

  • Sideris A, Malahias MA, Birch G, Zhong H, Rotundo V, Like BJ, Otero M, Sculco PK, Kirksey M. Identification of biological risk factors for persistent postoperative pain after total knee arthroplasty. Reg Anesth Pain Med. 2022 Mar;47(3):161-166. doi: 10.1136/rapm-2021-102953. Epub 2021 Dec 17.

    PubMed 34921052

  • Marsh J, Joshi I, Somerville L, Vasarhelyi E, Lanting B. Health care costs after total knee arthroplasty for satisfied and dissatisfied patients. Can J Surg. 2022 Sep 1;65(5):E562-E566. doi: 10.1503/cjs.006721. Print 2022 Sep-Oct.

    PubMed 36302132

  • Hawker GA, Guan J, Croxford R, Coyte PC, Glazier RH, Harvey BJ, Wright JG, Williams JI, Badley EM. A prospective population-based study of the predictors of undergoing total joint arthroplasty. Arthritis Rheum. 2006 Oct;54(10):3212-20. doi: 10.1002/art.22146.

    PubMed 17009255

  • Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis. 2011 Mar;70(3):523-9. doi: 10.1136/ard.2010.137844. Epub 2010 Nov 15.

    PubMed 21081524

  • Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum. 2005 May;52(5):1346-8. doi: 10.1002/art.21015. No abstract available.

    PubMed 15880805

  • Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford). 2005 Jan;44(1):7-16. doi: 10.1093/rheumatology/keh344. Epub 2004 Aug 3.

    PubMed 15292527

  • Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013 Jan;21(1):16-21. doi: 10.1016/j.joca.2012.11.012. Epub 2012 Nov 27.

    PubMed 23194896

  • Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S. The burden of musculoskeletal conditions. PLoS One. 2014 Mar 4;9(3):e90633. doi: 10.1371/journal.pone.0090633. eCollection 2014.

    PubMed 24595187

  • Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):421-6.

    PubMed 19407734

Questions about this trial

What is this clinical trial studying?

A study testing genicular artery embolization, Calibrated microspheres (100-300 µm) and Microcatheter in people with Angioembolization in Knee Osteoarthritis, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Rehab Awad Mohamed (2+01011511722, RehabAwad@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change from baseline in visual analog scale (VAS) pain score (time frame: Baseline and 6 months after the Procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07736248, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in